By Steven Ralston, CFANASDAQ:DSKEREAD THE FULL DSKE RESEARCH REPORTEXECUTIVE SUMMARY OF RECENT EVENTS‣ On February 7th, Daseke (NASDAQ:DSKE) preannounced select financial results for the fourth quarter and year ending December 31, 2018 and management provided financial guidance for 2019.     • Revenues for 2018 are anticipated to increase 90%+...
By John Vandermosten, CFANASDAQ:TTNPWe have now had more than two full quarters of in-house management of Probuphine commercialization by Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and indications are that shipment trends are strong. Since the company had their licenses returned in late May 2018 Titan has implemented a new strategy to...
By Steven Ralston, CFAOTC:PQEFF | TSX:PQEREAD THE FULL PQEFF RESEARCH REPORTPetroteq Energy (OTC:PQEFF) (TSX:PQE) is an upstream exploration and production (E&P) company focused on advancing its proprietary Clean Oil Recovery Technology (CORT). Currently, the company is ramping up bitumen oil production at its newly commissioned 1,000 bpd facility at...
By John Vandermosten, CFANYSE:CVMREAD THE FULL CVM RESEARCH REPORTWe are initiating coverage of CEL-SCI Corporation (NYSE:CVM) with a $14.00 price target based on our estimates for a 2021 US and 2022 EU launch of lead compound Multikine in squamous cell carcinoma of the head and neck (SCCHN). The clinical-stage...
By Steven Ralston, CFANASDAQ:MNGAREAD THE FULL MNGA RESEARCH REPORTMagneGas (NASDAQ:MNGA) / Taronis Technologies produces, sells and distributes a clean, hydrogen-based fuel synthesized through its proprietary, patented Plasma Arc Flow™ process. Currently, the largest commercial application is as an alternative to acetylene. Management is pursuing an aggressive acquisition strategy of...
By Lisa ThompsonNASDAQ:OIIMREAD THE FULL OIIM RESEARCH REPORTO2Micro (NASDAQ:OIIM) reported Q4 2018 revenues of $16.6 million, down slightly sequentially, but still up 9.0% year over year and within the range of guidance. Guidance for revenue for the fourth quarter of 2018 was sequentially flat plus or minus 5% from...
By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateNew Publication of Preclinical Data for OG716On January 28, 2019, Oragenics, Inc. (NYSE:OGEN) announced the publication of new preclinical data for the company’s lead lantibiotic development product, OG716, in the peer reviewed journal Antimicrobial Agents and Chemotherapy.Lantibiotics are a class...
By Brian Marckx, CFAOTC:PBSVREAD THE FULL PBSV RESEARCH REPORTFiscal 2018 Results: As Expected, Shedding of Lab Assets Benefits Profitability…Pharma-Bio Serv, Inc. (OTC:PBSV) filed their 10-K for their 2018 fiscal year ending October 31, 2018. This represents the first reporting period following the divestiture of their laboratory assets, the sale...
By John Vandermosten, CFANASDAQ:ATXIREAD THE FULL ATXI RESEARCH REPORTAvenue Therapeutics (NASDAQ:ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide...
By Brian Marckx, CFANASDAQ:ATOSREAD THE FULL ATOS RESEARCH REPORTQ3 Results / Business Update: Endoxifen Programs Progressing, FDA Grants Expanded Access…Atossa (NASDAQ:ATOS) announced results for their third quarter ending September 30th. As anticipated, no revenue was generated in the quarter. Operating expenses were $3.3M, up from $2.1M in the prior-year...